217 related articles for article (PubMed ID: 29239100)
1. Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.
Küffer S; Gutting T; Belharazem D; Sauer C; Michel MS; Marx A; Trojan L; Ströbel P
Mol Oncol; 2018 Feb; 12(2):256-266. PubMed ID: 29239100
[TBL] [Abstract][Full Text] [Related]
2. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor.
Vu TH; Hoffman A
J Biol Chem; 1996 Apr; 271(15):9014-23. PubMed ID: 8621549
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer.
Bhusari S; Yang B; Kueck J; Huang W; Jarrard DF
Prostate; 2011 Nov; 71(15):1621-30. PubMed ID: 21432864
[TBL] [Abstract][Full Text] [Related]
5. Altered imprinting, promoter usage, and expression of insulin-like growth factor-II gene in gestational trophoblastic diseases.
Kim SJ; Park SE; Lee C; Lee SY; Kim IH; An HJ; Oh YK
Gynecol Oncol; 2003 Mar; 88(3):411-8. PubMed ID: 12648595
[TBL] [Abstract][Full Text] [Related]
6. IGF2 DMR0 methylation, loss of imprinting, and patient prognosis in esophageal squamous cell carcinoma.
Murata A; Baba Y; Watanabe M; Shigaki H; Miyake K; Ishimoto T; Iwatsuki M; Iwagami S; Yoshida N; Oki E; Morita M; Nakao M; Baba H
Ann Surg Oncol; 2014 Apr; 21(4):1166-74. PubMed ID: 24318096
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma.
Li Y; Meng G; Huang L; Guo QN
Hum Pathol; 2009 Oct; 40(10):1441-7. PubMed ID: 19427670
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycemia from IGF2 overexpression associated with activation of fetal promoters and loss of imprinting in a metastatic hemangiopericytoma.
Lawson EA; Zhang X; Crocker JT; Wang WL; Klibanski A
J Clin Endocrinol Metab; 2009 Jul; 94(7):2226-31. PubMed ID: 19383775
[TBL] [Abstract][Full Text] [Related]
9. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting.
Li X; Adam G; Cui H; Sandstedt B; Ohlsson R; Ekström TJ
Oncogene; 1995 Jul; 11(2):221-9. PubMed ID: 7624139
[TBL] [Abstract][Full Text] [Related]
10. Alterations in promoter usage and expression levels of insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF-II.
Kim SJ; Park SE; Lee C; Lee SY; Jo JH; Kim JM; Oh YK
Biochim Biophys Acta; 2002 Apr; 1586(3):307-15. PubMed ID: 11997082
[TBL] [Abstract][Full Text] [Related]
11. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines.
Li T; Chen H; Li W; Cui J; Wang G; Hu X; Hoffman AR; Hu J
Hum Mol Genet; 2014 Jan; 23(1):117-28. PubMed ID: 23962719
[TBL] [Abstract][Full Text] [Related]
12. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate.
Fu VX; Dobosy JR; Desotelle JA; Almassi N; Ewald JA; Srinivasan R; Berres M; Svaren J; Weindruch R; Jarrard DF
Cancer Res; 2008 Aug; 68(16):6797-802. PubMed ID: 18701505
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression.
Dejeux E; Olaso R; Dousset B; Audebourg A; Gut IG; Terris B; Tost J
Endocr Relat Cancer; 2009 Sep; 16(3):939-52. PubMed ID: 19502451
[TBL] [Abstract][Full Text] [Related]
14. Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells.
Zhao X; Liu X; Wang G; Wen X; Zhang X; Hoffman AR; Li W; Hu JF; Cui J
Oncotarget; 2016 Aug; 7(32):51349-51364. PubMed ID: 27275535
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
[TBL] [Abstract][Full Text] [Related]
16. A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate.
Dobosy JR; Fu VX; Desotelle JA; Srinivasan R; Kenowski ML; Almassi N; Weindruch R; Svaren J; Jarrard DF
Prostate; 2008 Aug; 68(11):1187-95. PubMed ID: 18459101
[TBL] [Abstract][Full Text] [Related]
17. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.
Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP
Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665
[TBL] [Abstract][Full Text] [Related]
18. Loss of imprinting and promoter usage of the IGF2 in laryngeal squamous cell carcinoma.
Grbesa I; Ivkic M; Pegan B; Gall-Troselj K
Cancer Lett; 2006 Jul; 238(2):224-9. PubMed ID: 16111804
[TBL] [Abstract][Full Text] [Related]
19. Loss of
Damaschke NA; Yang B; Bhusari S; Avilla M; Zhong W; Blute ML; Huang W; Jarrard DF
Cancer Res; 2017 Oct; 77(19):5236-5247. PubMed ID: 28775169
[TBL] [Abstract][Full Text] [Related]
20. Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Mar; 35(3):1511-8. PubMed ID: 26676988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
